Galectin Therapeutics reported $-7.42M in EBITDA for its fiscal quarter ending in December of 2021.





Ebitda Change Date
AbbVie USD 3.69B 1.68B Mar/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Galectin Therapeutics USD -7.42M 819K Dec/2021
Gilead Sciences USD 3.51B 489M Mar/2026
Immunic USD -22.78M 753K Jun/2024
Incyte USD 778.57M 410.6M Jun/2026
Merck USD -1.54B 7.84B Mar/2026